New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
11:05 EDTRGP, IRWD, DMND, CMLP, WYN, JE, JNS, TPH, BKD, ALIMHigh option volume stocks
High option volume stocks: ALIM BKD TPH JNS JE WYN CMLP DMND IRWD RGP
News For ALIM;BKD;TPH;JNS;JE;WYN;CMLP;DMND;IRWD;RGP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 24, 2014
06:36 EDTWYNWyndham approves $1B increase to share repurchase authorization
Subscribe for More Information
06:34 EDTWYNWyndham sees FY15 EPS $4.70-$4.85, consensus $4.97
Subscribe for More Information
06:33 EDTWYNWyndham raises FY14 adjusted EPS view to $4.45-$4.48 from $4.34-$4.44
Subscribe for More Information
06:31 EDTWYNWyndham reports Q3 adjusted EPS $1.67, consensus $1.63
Reports Q3 revenue $1.53B, consensus $1.53B.
October 23, 2014
15:39 EDTWYNNotable companies reporting before tomorrow's open
Subscribe for More Information
13:44 EDTJNSFollow-up: Janus Capital downgraded to Sell at Citigroup
Citigroup downgraded Janus Capital to Sell from Neutral citing margin pressure and its belief the market is too optimistic on Bill Gross-related inflows. Citi lowered its price target for shares to $12.50 from $14.50 following the company's Q3 results.
13:29 EDTJNSJanus Capital downgraded to Sell from Neutral at Citigroup
Subscribe for More Information
10:42 EDTALIMHigh option volume stocks
High option volume stocks: ALIM ROC CAKE MDXG SMH CFX CRI INFN LTM
10:01 EDTRGPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 3D Systems (DDD) downgraded to Hold from Buy at Brean Capital... Angie's List (ANGI) downgraded to Hold from Buy at Needham... Avalon Rare Metals (AVL) downgraded to Neutral from Buy at Citigroup... Axiall (AXLL) downgraded at Cowen... BB&T (BBT) downgraded to Neutral from Buy at Goldman... Boeing (BA) downgraded at Credit Suisse... Boulder Brands (BDBD) downgraded to Hold from Buy at Canaccord... Citrix (CTXS) downgraded to Hold from Buy at Drexel Hamilton... ClickSoftware (CKSW) downgraded to Hold from Buy at Lake Street... DTS, Inc. (DTSI) downgraded to Underweight from Neutral at JPMorgan... GulfMark Offshore (GLF) downgraded to Market Perform from Outperform at Cowen... Home Loan Servicing (HLSS) downgraded to Neutral from Buy at Compass Point... ICON plc (ICLR) downgraded to Equal Weight from Overweight at First Analysis... IPC The Hospitalist Co. (IPCM) downgraded to Market Perform at Wells Fargo... Melco Crown (MPEL) downgraded to Neutral from Buy at Nomura... Mercer (MERC) downgraded at Credit Suisse... ONEOK Partners (OKS) downgraded to Neutral from Buy at BofA/Merrill... Owens Corning (OC) downgraded to Neutral from Overweight at JPMorgan... Regency Energy Partners (RGP) downgraded to Neutral from Buy at BofA/Merrill... The Medicines Co. (MDCO) downgraded to Neutral from Buy at BofA/Merrill... Tupperware Brands (TUP) downgraded to Neutral from Overweight at JPMorgan... Union Bankshares (UBSH) downgraded at RW Baird... VOC Energy Trust (VOC) downgraded at RBC Capital... Yelp (YELP) downgraded to Hold from Buy at Stifel.
07:02 EDTJNSJanus Capital reports Q3 EPS 22c, consensus 22c
Subscribe for More Information
06:47 EDTRGPRegency Energy Partners downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
October 20, 2014
08:08 EDTIRWDIronwood presents IW-9179 Phase IIa clinical study data
Subscribe for More Information
October 17, 2014
15:53 EDTALIMJames E. Flynn reports 5.58% passive stake in Alimera Sciences
Subscribe for More Information
October 16, 2014
15:10 EDTIRWDAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
08:02 EDTIRWDIronwood announces initiation of Phase II linaclotide trial
Ironwood Pharmaceuticals (IRWD) announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc (ACT), Ironwood’s co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.
07:23 EDTALIMIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 15, 2014
11:03 EDTWYNNew York AG reaches agreements with Hilton, Wyndham over timeshares
Subscribe for More Information
10:49 EDTRGPHigh option volume stocks
High option volume stocks: SNV FCG TXT MDSO PPHM NTRS CCL RGP LLTC SOCL
October 13, 2014
17:15 EDTCMLPCrestwood Midstream says Q3 average natural gas gathering volumes up 5%
Subscribe for More Information
08:04 EDTJNSJanus to acquire VelocityShares, includes upfront cash consideration of $30M
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use